Advertisement for orthosearch.org.uk
Results 1 - 20 of 41
Results per page:
The Bone & Joint Journal
Vol. 106-B, Issue 11 | Pages 1197 - 1198
1 Nov 2024
Haddad FS


The Bone & Joint Journal
Vol. 106-B, Issue 11 | Pages 1199 - 1202
1 Nov 2024
Watts AC Tennent TD Haddad FS


Bone & Joint 360
Vol. 13, Issue 5 | Pages 5 - 6
1 Oct 2024
Ollivere B


The Bone & Joint Journal
Vol. 106-B, Issue 9 | Pages 884 - 886
1 Sep 2024
Brown R Bendall S Aronow M Ramasamy A


The Bone & Joint Journal
Vol. 106-B, Issue 3 Supple A | Pages 1 - 2
1 Mar 2024
Haddad FS Berry DJ


Bone & Joint Research
Vol. 12, Issue 10 | Pages 654 - 656
16 Oct 2023
Makaram NS Simpson AHRW

Cite this article: Bone Joint Res 2023;12(10):654–656.


Bone & Joint Research
Vol. 12, Issue 8 | Pages 494 - 496
9 Aug 2023
Clement ND Simpson AHRW

Cite this article: Bone Joint Res 2023;12(8):494–496.


The Bone & Joint Journal
Vol. 105-B, Issue 6 | Pages 590 - 592
1 Jun 2023
Manktelow ARJ Mitchell P Haddad FS

Cite this article: Bone Joint J 2023;105-B(6):590–592.


Bone & Joint Research
Vol. 12, Issue 5 | Pages 311 - 312
5 May 2023
Xu C Liu Y

Cite this article: Bone Joint Res 2023;12(5):311–312.


Bone & Joint 360
Vol. 11, Issue 5 | Pages 3 - 4
1 Oct 2022
Ollivere B


Bone & Joint 360
Vol. 11, Issue 2 | Pages 3 - 4
1 Apr 2022
Ollivere B


The Bone & Joint Journal
Vol. 103-B, Issue 12 | Pages 1743 - 1744
1 Dec 2021
Haddad FS


Bone & Joint Research
Vol. 10, Issue 9 | Pages 571 - 573
2 Sep 2021
Beverly MC Murray DW


Bone & Joint 360
Vol. 10, Issue 4 | Pages 3 - 4
1 Aug 2021
Ollivere B


Bone & Joint Research
Vol. 10, Issue 2 | Pages 134 - 136
1 Feb 2021
Im G

The high prevalence of osteoarthritis (OA), as well as the current lack of disease-modifying drugs for OA, has provided a rationale for regenerative medicine as a possible treatment modality for OA treatment. In this editorial, the current status of regenerative medicine in OA including stem cells, exosomes, and genes is summarized along with the author’s perspectives. Despite a tremendous interest, so far there is very little evidence proving the efficacy of this modality for clinical application. As symptomatic relief is not sufficient to justify the high cost associated with regenerative medicine, definitive structural improvement that would last for years or decades and obviate or delay the need for joint arthroplasty is essential for regenerative medicine to retain a place among OA treatment methods.

Cite this article: Bone Joint Res 2021;10(2):134–136.


The Bone & Joint Journal
Vol. 102-B, Issue 10 | Pages 1274 - 1276
3 Oct 2020
Tsang SJ Eyre DW Atkins BL Simpson AHRW


The Bone & Joint Journal
Vol. 102-B, Issue 10 | Pages 1271 - 1273
1 Oct 2020
Scott CEH Simpson AHRW Pankaj P


The Bone & Joint Journal
Vol. 102-B, Issue 9 | Pages 1109 - 1110
14 Sep 2020
Haddad FS


Bone & Joint 360
Vol. 9, Issue 3 | Pages 3 - 3
1 Jun 2020
Ollivere B


The Bone & Joint Journal
Vol. 102-B, Issue 6 | Pages 658 - 660
1 Jun 2020
Judge A Metcalfe D Whitehouse MR Parsons N Costa M